

Financial Statements of

**THE WELLSRING CANCER
SUPPORT FOUNDATION**

And Independent Auditor's Report thereon

Year ended March 31, 2024



KPMG LLP

Vaughan Metropolitan Centre
100 New Park Place, Suite 1400
Vaughan, ON L4K 0J3
Canada
Telephone 905 265 5900
Fax 905 265 6390

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of The Wellspring Cancer Support Foundation

Qualified Opinion

We have audited the financial statements of The Wellspring Cancer Support Foundation (the Entity), which comprise:

- the statement of financial position as at March 31, 2024
- the statement of operations for the year then ended
- the statement of changes in net assets for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, except for the possible effect of the matter described in the "***Basis for Qualified Opinion***" section of our auditor's report, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2024, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Qualified Opinion

In common with many not-for-profit organizations, the Entity derives revenue from donations, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Entity.

Therefore, we were not able to determine whether any adjustments might be necessary to:

- the current assets reported in the statements of financial position as at March 31, 2024 and March 31, 2023
- the donations revenue and excess (deficiency) of revenue over expenses reported in the statements of operations for the years ended March 31, 2024 and March 31, 2023
- the unrestricted net assets at the beginning and end of the year reported in the statements of changes in net assets for the years ended March 31, 2024 and March 31, 2023
- the excess (deficiency) of revenue over expenses reported in the statements of cash flows for the years ended March 31, 2024 and March 31, 2023.



Page 2

Our opinion on the financial statements for the year ended March 31, 2023 was qualified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "**Auditor's Responsibilities for the Audit of the Financial Statements**" section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.



Page 3

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

A handwritten signature in black ink that reads 'KPMG LLP' in a cursive, slightly slanted font. A horizontal line is drawn underneath the signature.

Chartered Professional Accountants, Licensed Public Accountants

Vaughan, Canada

June 7, 2024

THE WELLSRING CANCER SUPPORT FOUNDATION

Statement of Financial Position

March 31, 2024, with comparative information for 2023


	2024	2023
Assets		
Current assets:		
Cash	\$ 435,587	\$ 385,982
Short-term investments (note 2)	4,138,340	4,804,290
Accounts receivable	173,153	158,694
Prepaid expenses and deposits	98,906	159,565
	<u>4,845,986</u>	<u>5,508,531</u>
Investments (note 3):		
Long-term investments	2,203,768	1,747,591
Endowment funds	447,430	447,430
	<u>2,651,198</u>	<u>2,195,021</u>
Capital assets (note 4)	3,305,211	3,332,131
	<u>\$ 10,802,395</u>	<u>\$ 11,035,683</u>

Liabilities and Net Assets

Current liabilities:		
Accounts payable and accrued charges	\$ 1,042,452	\$ 941,302
Deferred revenue (note 5)	179,349	100,587
	<u>1,221,801</u>	<u>1,041,889</u>
Deferred contributions (note 6)	2,896,337	3,106,836
Net assets:		
Restricted (note 7)	1,685,466	1,685,466
Invested in capital assets	428,700	311,330
Unrestricted	4,570,091	4,890,162
	<u>6,684,257</u>	<u>6,886,958</u>
Commitments (note 8)		
	<u>\$ 10,802,395</u>	<u>\$ 11,035,683</u>

See accompanying notes to financial statements.

On behalf of the Board:

 Director

 Director

THE WELLSPRING CANCER SUPPORT FOUNDATION

Statement of Operations

March 31, 2024, with comparative information for 2023

	2024	2023
Revenue:		
Special events	\$ 1,081,208	\$ 1,028,707
Donations (note 6)	1,944,933	4,292,067
Amortization of deferred contributions (note 6)	280,323	265,651
Other (note 8)	127,397	47,272
Investment	242,723	132,063
Social enterprise	158,853	142,444
Unrealized gain on investments	416,889	14,095
	<u>4,252,326</u>	<u>5,922,299</u>
Expenses:		
Program (note 5)	2,937,884	2,353,459
Special events	464,653	474,469
Fundraising	595,654	594,545
Administration	75,628	231,629
Amortization	296,227	309,879
Public awareness	84,983	86,860
Unrealized loss on investments	--	--
	<u>4,455,029</u>	<u>4,050,841</u>
Excess (deficiency) of revenue over expenses	\$ (202,703)	\$ 1,871,458

See accompanying notes to financial statements.

THE WELLSRING CANCER SUPPORT FOUNDATION

Statement of Changes in Net Assets

Year ended March 31, 2024, with comparative information for 2023

				2024	2023
	Restricted (note 7)	Invested in capital assets	Unrestricted	Total	Total
Net assets, beginning of year	\$ 1,685,466	\$ 311,332	\$ 4,890,162	\$ 6,886,960	\$ 5,015,502
Excess (deficiency) of revenue over expenses	--	(15,904)	(186,799)	(202,703)	1,871,458
Additions to capital assets, net of amounts funded by deferred capital contributions	--	133,272	(133,272)	--	--
Net assets, end of year	\$ 1,685,466	\$ 428,700	\$ 4,570,091	\$ 6,684,257	\$ 6,886,960

See accompanying notes to financial statements.

THE WELLSPRING CANCER SUPPORT FOUNDATION

Statement of Cash Flows

Year ended March 31, 2024, with comparative information for 2023

	2024	2023
Cash provided by (used in):		
Operating activities:		
Excess (deficiency) of revenue over expenses	\$ (202,703)	\$ 1,871,458
Items not involving cash:		
Amortization of deferred contributions	(280,323)	(265,651)
Amortization	296,227	309,879
Unrealized gain on investments	(416,889)	(14,095)
	(603,688)	1,901,591
Change in non-cash operating working capital:		
Accounts receivable	(14,459)	(84,701)
Prepaid expenses and deposits	60,659	(77,684)
Accounts payable and accrued charges	101,150	336,440
Deferred revenue	78,762	(34,655)
	(377,576)	2,040,991
Financing activities:		
Deferred contributions received	69,826	314,888
Investing activities:		
Increase in short-term investments, net	665,950	(1,917,763)
Increase (decrease) in long-term investments, net	(39,288)	87,124
Additions to capital assets	(269,307)	(417,208)
	357,355	(2,247,847)
Increase in cash	49,605	108,032
Cash, beginning of year	385,982	277,950
Cash, end of year	\$ 435,587	\$ 385,982

See accompanying notes to financial statements.

THE WELLSRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements

Year ended March 31, 2024

The Wellspring Cancer Support Foundation ("Wellspring") opened on May 1, 1992 for the purpose of providing: support programs and services for people and their families living with cancer; opportunities for the development of self-help skills leading to an enhanced quality of life; access to information; education for health care professionals; and evaluation and research into the benefits of supportive care. Wellspring was previously incorporated, without share capital, under the Canada Corporations Act on January 19, 1996, is a registered charity and, therefore, exempt from income taxes under the Income Tax Act (Canada). Wellspring was continued under the Canada Not-for-profit Corporations Act in October 2014.

From its inception in 1992 until December 1999, Wellspring provided its programs and services from one location, namely its facility at 81 Wellesley Street East in Toronto. In December 1999, Wellspring opened a new facility on the campus of Sunnybrook & Women's College Health Sciences Centre (now called Wellspring Westerkirk House at Sunnybrook) and, in July 2000, another in Oakville, Ontario (now called Wellspring Birmingham Gilgan House), to serve the regions of Halton and Peel. Wellspring also offers programs online.

Substantial expansion and renovation projects were completed at Wellspring Westerkirk House (2010) and Wellspring Birmingham Gilgan House (2012) and the original Wellspring centre at 81 Wellesley Street East was sold in 2011, with downtown operations and programs relocated to 4 Charles Street East, also in downtown Toronto, in 2012. Wellspring no longer operates a facility in downtown Toronto but delivers programs in other venues, such as hospitals, and has a robust online program delivery presence.

There are affiliated Wellspring centres in Brampton, Niagara and London, Ontario, and in Calgary and Edmonton, Alberta. All are separately incorporated and separately governed.

Wellspring receives no core government funding.

1. Significant accounting policies:

These financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations.

(a) Revenue recognition:

Wellspring follows the deferral method of accounting for contributions. Restricted donations are recognized as revenue in the year in which the related expenses are incurred. Unrestricted donations are recognized as revenue when received.

THE WELLSPRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

1. Significant accounting policies (continued):

Contributions restricted for the purchase of capital assets are deferred and amortized into revenue at a rate corresponding with the amortization rate for related capital assets. Endowment contributions are recognized as direct increases in net assets.

Restricted investment income is recognized as revenue in the year in which the related expenses are incurred. Unrestricted investment income is recognized as revenue when earned. Investment income earned on endowment funds is recognized as revenue when earned.

Pledges are recognized when money is received.

(b) Financial instruments:

Financial instruments are recorded at fair value on initial recognition. Freestanding derivative instruments that are not in a qualifying hedging relationship and equity instruments that are quoted in an active market are subsequently recorded at fair value. All other financial instruments are subsequently measured at cost or amortized cost, unless management has elected to carry the instruments at fair value. Wellspring has not elected to carry any such financial instruments at fair value.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, Wellspring determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount Wellspring expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future year, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(c) Capital assets:

Purchased capital assets are recorded at cost. Contributed capital assets are recorded at fair value at the date of contribution. Repairs and maintenance costs are charged to expense. Betterments which extend the estimated life of an asset are capitalized. When a capital asset no longer contributes to Wellspring's ability to provide services, its carrying amount is written down to its residual value.

THE WELLSRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

1. Significant accounting policies (continued):

Capital assets are amortized on a straight-line basis over the estimated useful lives of the assets as follows:

Furniture and equipment	5 years
Computer hardware	3 years
Digital platform	5 years
Leasehold improvements	10 - 25 years

Artwork is not amortized. The digital platform is currently being developed and has not begun to be amortized.

(d) Donated materials and services:

Wellspring recognizes the contribution of materials at fair value when it can be reasonably estimated, when it is used in the normal course of operations and would have been otherwise purchased. Because of the difficulty in determining the fair value, contributed services and volunteer time is not recognized in the financial statements.

(e) Government assistance:

Government assistance related to current revenue and expenses is included in the determination of excess (deficiency) of revenue over expenses for the year.

(f) Use of estimates:

The preparation of Wellspring's financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Significant items subject to such estimates and assumptions include the carrying amount of capital assets. Actual results could differ from those estimates.

THE WELLSPRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

2. Short-term investments:

	2024	2023
Shares	\$ —	\$ 37,164
Money market funds	960,743	2,516,140
Short-term bond fund	3,177,597	2,250,986
	\$ 4,138,340	\$ 4,804,290

3. Investments:

In 2014, the finance committee proposed and the Board of Directors adopted an investment policy allowing for a portion of the deferred capital to be invested in a long-term capital fund managed by Jarislowsky Fraser Ltd.

	2024	2023
Canadian Equity Fund	\$ 1,066,534	\$ 921,146
Global Equity Fund	1,584,664	1,273,875
	\$ 2,651,198	\$ 2,195,021

Endowment funds of \$447,430 (2023 - \$447,430) are invested in long-term investments.

4. Capital assets:

			2024	2023
	Cost	Accumulated amortization	Net book value	Net book value
Furniture and equipment	\$ 438,363	\$ 412,838	\$ 25,525	\$ 25,370
Computer hardware	350,373	312,385	37,988	61,798
Digital platform	629,560	6,810	622,750	384,399
Leasehold improvements	5,655,262	3,225,333	2,429,929	2,671,545
Artwork	189,019	--	189,019	189,019
	\$ 7,262,577	\$ 3,957,366	\$ 3,305,211	\$ 3,332,131

THE WELLSRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

5. Deferred revenue:

	2024	2023
Balance, beginning of year	\$ 100,587	\$ 135,242
Contributions received:		
Peloton Challenge	18,237	5,986
Other	129,494	89,194
Amounts recognized as revenue:		
Peloton Challenge	(4,987)	(54,414)
Other	(63,982)	(75,421)
Balance, end of year	\$ 179,349	\$ 100,587

6. Deferred contributions:

Deferred contributions represent contributions and donations in-kind for the buildings and other projects. The changes in the deferred contributions balance for the year are as follows:

	2023	Additions	Amortization	Transfer from operating to capital	2024
Capital:					
Westerkirk House	\$ 1,194,570	\$ --	\$ (157,341)	\$ --	\$ 1,037,229
Birmingham Gilgan House	1,377,415	--	(94,452)	--	1,282,963
Digital platform	384,398	136,035	(3,779)	--	516,654
Computers	50,006	--	(21,773)	--	28,233
Equipment	14,410	--	(2,978)	--	11,432
	3,020,799	136,035	(280,323)	--	2,876,511
Operating:					
Fidelity - IT/website	86,037	69,824	--	(136,035)	19,826
	\$ 3,106,836	\$ 205,859	\$ (280,323)	\$ (136,035)	\$ 2,896,337

THE WELLSPRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

7. Restricted net assets:

	2024	2023
Externally restricted for endowment	\$ 447,430	\$ 447,430
Internally restricted	1,238,036	1,238,036
	<u>\$ 1,685,466</u>	<u>\$ 1,685,466</u>

Internally restricted net assets have been designated by the Board of Directors to be used for working capital purposes. These internally restricted amounts are not available for other purposes without approval of the Board of Directors.

8. Commitments:

Wellspring leases and office equipment under an operating lease expiring 2025. Future minimum lease payments under these leases are as follows:

Year ending March 31:	
2025	\$ 3,100

Wellspring leases premises for nominal fees under long-term leases for the operations of two of its centres. The Westerkirk House lease expires in 2029 and the Birmingham Gilgan House expires in 2039. Both leases include an option to extend the terms of the lease.

9. Financial risks:

(a) Market price risk:

Market price risk is the risk that the value of an instrument will fluctuate as a result of changes in market prices, whether those changes are caused by factors specific to an individual investment, its issuer or all factors affecting all instruments traded in the market. As all of Wellspring's investments are carried at fair value with fair value changes recognized in the statement of operations, all changes in market conditions will directly result in an increase (decrease) in the excess (deficiency) of revenue over expenses. There has been no change to the risk exposure from 2023.

THE WELLSRING CANCER SUPPORT FOUNDATION

Notes to Financial Statements (continued)

Year ended March 31, 2024

9. Financial risks (continued):

(b) Credit risk:

Credit risk arises as a result of the possibility that one party to a financial instrument will fail to discharge an obligation and cause Wellspring to incur financial loss. Wellspring manages this risk by diversifying its portfolio and by dealing with reputable and creditworthy counterparties. There has been no change to the risk exposure from 2023.

(c) Interest rate risk:

Wellspring is exposed to interest rate risk on its fixed interest rate financial instruments. The value of fixed income funds will generally rise if interest rates rise and decrease if interest rates fall. Changes in interest may also affect the value of equity securities. The interest rate risk exposure is managed through the Board of Directors-approved policy of allocation of investable assets. There has been no change to the risk exposure from 2023.

10. Comparative information:

Certain comparative information has been adjusted in the current year.

